OncoMed Pharmaceuticals
Improving cancer treatment by creating novel medicines.
Launch date
Employees
Market cap
-
Enterprise valuation
$89—133m (Dealroom.co estimates Dec 2013.)
Redwood City California (HQ)
Financials
Estimates*
| USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | - | - | 38.0m | 44.0m | 34.0m | 27.0m |
| % growth | - | - | - | 16 % | (23 %) | (21 %) |
| Profit | - | - | (39.0m) | (8.0m) | (18.0m) | (18.0m) |
| % profit margin | - | - | (103 %) | (18 %) | (53 %) | (67 %) |
| R&D budget | 68.2m | 92.4m | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$13.9m | Series A | ||
$154m | Series B | ||
| N/A | $20.0m | Late VC | |
| N/A | $81.6m | IPO | |
| N/A | $22.2m | Late VC | |
| Total Funding | $210m | ||
Related Content
Recent News about OncoMed Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.